Funded Health Care Startups in San Mateo
Among the 10 most recent health care rounds listed for San Mateo, the largest disclosed round is Truepill’s $142M (2021-10-27).
Among the 10 most recent health care rounds listed for San Mateo, the largest disclosed round is Truepill’s $142M (2021-10-27). That figure dwarfs the rest: only one other disclosed amount sits above $50M (Route 92 Medical’s $50M on 2024-07-12), while multiple entries cluster between $14M and $20M (e.g., Aclarion $14M in 2025-01-15, Bold $17M in 2023-09-12, EndoGastric Solutions $18M in 2022-12-06, Foundation Health $20M in 2025-10-12). The rounds span a wide temporal edge—2021-08-18 (Opya) through 2025-10-12—yet the recent half is concentrated in 2023–2025, with several $10M–$20M disclosures.
Stage reporting is also uneven: 3 of 10 entries are labeled “Series Unknown” (Aclarion 2025-01-15 $14M; Route 92 Medical 2024-07-12 $50M; EndoGastric Solutions 2022-12-06 $18M). The remaining named stages skew toward higher-ticket fundraising compared with the smaller early outliers—Trek Health’s $3M (Seed, 2022-09-09) and Meru Health’s $2M (Grant, 2022-05-10). Geographic placement is consistent with all rows listing San Mateo, California, United States.
Most recent rounds
10 shownRelated listings
Frequently asked
What’s the largest disclosed round in this San Mateo health care list, and how does it compare to the rest?
Truepill’s $142M (2021-10-27) is the clear outlier. The next-largest disclosed amounts are Route 92 Medical at $50M (2024-07-12) and Foundation Health at $20M (2025-10-12), with most other disclosed rounds falling in the $14M–$18M range (e.g., Aclarion $14M on 2025-01-15; EndoGastric Solutions $18M on 2022-12-06).
Do these rounds cluster in a particular date window, or are they evenly spread across years?
The 10 rounds span from 2021-08-18 (Opya) to 2025-10-12 (Foundation Health). Several larger, more recent disclosures concentrate in 2023–2025, including Foundation Health $20M (2025-10-12), Aclarion $14M (2025-01-15), and Route 92 Medical $50M (2024-07-12), whereas the earliest entries include Opya $15M (2021-08-18) and Truepill $142M (2021-10-27).
How much of the sample has “Series Unknown,” and does it include the top dollar amounts?
3 of 10 entries are labeled “Series Unknown” (Aclarion $14M on 2025-01-15; Route 92 Medical $50M on 2024-07-12; EndoGastric Solutions $18M on 2022-12-06). The only disclosed amount above $50M is Truepill’s $142M (Series D), while Route 92 Medical’s $50M sits at the high end even with “Series Unknown.”
Is stage mix skewed toward a particular fundraising level, especially compared with early-stage/low-dollar rounds?
Higher disclosed rounds recur at named or later stages: Foundation Health ($20M, Series A, 2025-10-12) and Bold ($17M, Series A, 2023-09-12) sit near the middle-high range. In contrast, the smallest disclosed amounts are Trek Health’s $3M (Seed, 2022-09-09) and Meru Health’s $2M (Grant, 2022-05-10), making these low-dollar entries clear bottom-end anchors.
Are there any notable outliers besides the biggest round, such as a much smaller deal size or a distinct reporting pattern?
Beyond the $142M outlier (Truepill, 2021-10-27), the bottom end is anchored by Meru Health’s $2M grant (2022-05-10) and Trek Health’s $3M seed (2022-09-09), both substantially below the typical $14M–$20M cluster. Reporting is also asymmetric: 3/10 entries are “Series Unknown,” but most of the remaining stages are explicitly labeled (e.g., Foundation Health Series A, Truepill Series D).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.